Evaluating Stress Response and Anxiety Score in Paediatric Patients

• Status: Completed
• Trial end date: 2021-08-01
• Target enrollment: 0
• Participant gender: All

Summary

To date, there have been no studies done relating serum cortisol levels and intranasal dexmedetomidine sedation. However, there was a behavioral study done on pediatric patients confirming reduction serum cortisol levels with perioperative dialogue intervention.There have been a number of studies done on adult patients indicating that dexmedetomidine was indeed capable of reducing level of anxiety with evidence of lower serum cortisol levels. Hence, we postulated that intranasal dexmedetomidine administration in pediatric patients will lower the serum cortisol levels but we need to evaluate the extent of reduction.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Universiti Sains Malaysia
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Pediatric patients age 1-12 years old

• Weight of patient between 10 - 60 kgs

• American Society of Anesthesiologist (ASA) I or II

• Scheduled for elective and emergency surgeries

• Caregivers able to understand and provide informed consent

Exclusion Criteria:

• Allergy to study drugs (dexmedetomidine, morphine, paracetamol etc.)

• Special need Children (Cerebral palsy, down syndrome, ADHD, ASD)

• Serious cardiac/respiratory diseases.

• Children with neuromuscular disorders or neurological diseases (epilepsy etc)

• Children with Metabolic disorders

• Difficult airway cases

• Children on any kind of steroid therapy / HPA diseases